Novartis: Sandoz signs deal for constipation drug
(CercleFinance.com) - Novartis' generic drugs unit Sandoz has signed an agreement with Japan's Shionogi to commercialize a new treatment for opioid induced constipation.
Under the terms of the agreement, Sandoz will be responsible for commercializing Rizmoic in Germany, the UK and the Netherlands.
Rizmoic - a once-daily oral tablet that was discovered and developed by Shionogi - is indicated to treat opioid induced constipation in adult patients previously treated with a laxative. The drug was approved by the EU in February.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Under the terms of the agreement, Sandoz will be responsible for commercializing Rizmoic in Germany, the UK and the Netherlands.
Rizmoic - a once-daily oral tablet that was discovered and developed by Shionogi - is indicated to treat opioid induced constipation in adult patients previously treated with a laxative. The drug was approved by the EU in February.
Copyright (c) 2019 CercleFinance.com. All rights reserved.